tiprankstipranks
Trending News
More News >

Haleon Completes Acquisition of Remaining Stake in China JV

Story Highlights
  • Haleon PLC completed the acquisition of the remaining 12% in its China joint venture.
  • This acquisition enhances Haleon’s strategic and operational flexibility in the Chinese market.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Haleon Completes Acquisition of Remaining Stake in China JV

Confident Investing Starts Here:

Haleon PLC Sponsored ADR ( (HLN) ) just unveiled an announcement.

On June 27, 2025, Haleon PLC announced the completion of its acquisition of the remaining 12% equity interest in Tianjin TSKF Pharmaceutical Co. Ltd, making it a wholly owned subsidiary. This strategic move, initially announced on April 15, 2025, for RMB 1,623 million, strengthens Haleon’s position in the Chinese market, which is crucial for its growth due to favorable structural drivers. The acquisition enhances Haleon’s operational flexibility and aligns with its capital allocation priorities, promising attractive returns for shareholders and maintaining a strong investment-grade balance sheet.

The most recent analyst rating on (HLN) stock is a Buy with a $13.40 price target. To see the full list of analyst forecasts on Haleon PLC Sponsored ADR stock, see the HLN Stock Forecast page.

Spark’s Take on HLN Stock

According to Spark, TipRanks’ AI Analyst, HLN is a Outperform.

Haleon’s strong financial performance, characterized by robust cash flow and stable profitability, is a key strength, complemented by positive technical indicators suggesting upward momentum. However, the stock’s valuation appears high, and recent earnings call highlights both opportunities in emerging markets and challenges like FX headwinds and product performance issues. These factors collectively position the stock at a solid yet cautious 73.1 score.

To see Spark’s full report on HLN stock, click here.

More about Haleon PLC Sponsored ADR

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health through its extensive portfolio of products. The company operates across six major categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon is known for its long-standing brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren, which are built on trusted science and innovation.

Average Trading Volume: 16,337,882

Technical Sentiment Signal: Buy

Current Market Cap: $47.32B

For an in-depth examination of HLN stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1